For research use only. Not for therapeutic Use.
VU591 is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC50 of 0.24 μM. VU591 can be used for neurological research with HY-108585 (the equivalent of VU591 hydrochloride)[1].
VU591 is a selective ROMK inhibitor and a ROMK channel pore blocker. VU591 can bind serum protein and has high metabolic stability[1].
VU591 (i.c.v.; 1.842 μg) significantly decreases the immobile time in TST[2].
| Catalog Number | I012442 |
| CAS Number | 1222810-74-3 |
| Synonyms | 6-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole |
| Molecular Formula | C16H12N6O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H12N6O5/c23-21(24)9-1-3-11-13(5-9)19-15(17-11)7-27-8-16-18-12-4-2-10(22(25)26)6-14(12)20-16/h1-6H,7-8H2,(H,17,19)(H,18,20) |
| InChIKey | ZQPXNYLXYNRFNP-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1[N+](=O)[O-])NC(=N2)COCC3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-] |
| Reference | [1]. Bhave G, et al. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011 Jan;79(1):42-50. [2]. Masayoshi Okada, et al. Antidepressive effect of an inward rectifier K+ channel blocker peptide, tertiapin-RQ. PLoS One. 2020 Nov 13;15(11):e0233815. |
